Watson Biologics Enters Strategic Partnership with Zhiyu Bio to Accelerate Vaccine R&D Using AI

Walvax Biotechnology Co., Ltd.Walvax Biotechnology Co., Ltd. (referred to as "Walvax")In Collaboration with Zelixir, a Pioneer in AI-Driven Synthetic Biology InnovationZelixir) recentlyEstablish a strategic partnership.

This collaboration aims to deeply integrate Walvax.The profound strength in vaccine research, production, and industrialization, combined with Zelixir's cutting-edge technology in AI-driven biocomputing,Jointly explore the application of artificial intelligence technology in the research, production, and commercialization of human vaccines, accelerating technological innovation and the intelligent process in the vaccine industry.

Based on the principles of equality and mutual benefit, as well as complementary advantages, the core of this strategic cooperation between the two parties isApply Zelixir's world-leading bio-computation technology, which combines AI modeling with physical simulation, to Walvax's human vaccine research and development field.The key points include utilizingAI Technology Accelerates the Discovery and Design of Proteins (Including Enzymes) and Other Process Development, Providing AI Bio-computation Platform Licensing Services to Build an Intelligent R&D FoundationFacilities, and provide deeply customized AI biological computing solutions based on the specific needs of vaccine products.

AI technology is profoundly transforming the paradigm of vaccine development, particularly in target identification, antigen design, and immunogenicity prediction.The application has significantly improved R&D efficiency. The collaboration between Walvax and Zelixir marks an important step in the deep integration of the biopharmaceutical industry with cutting-edge artificial intelligence technology.

Both parties will fully leverage their respective advantages in vaccine R&D industrialization and AI biocomputing, committing to enhancing the efficiency and success rate of vaccine development through technological innovation.To drive the new quality productive forces in China's vaccine industry towards intelligent and green upgrades. This collaboration will not only provide strong technological support for Walvax to build a world-class vaccine enterprise, but also aims to jointly contribute innovative strength to the implementation of the "Healthy China" strategy and the development of global public health, leading humanity towards a healthier and more sustainable future.